Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARMAC: Standard of Care Chemotherapy in Nigerian Women with TNBC
NCT06291064Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Mar 2025
- Primary completion
- Jun 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of epirubicin, cyclophosphamide, docetaxel, carboplatin in triple-negative breast cancer (TNBC), sponsored by University of Chicago. Started Mar 2025; status: recruiting.
02
Drugs
epirubicincyclophosphamidedocetaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06291064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291064.